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Microglia: A Promising Target for Treating Neuropathic
and Postoperative Pain, and Morphine Tolerance
Yeong-Ray Wen,1,2,3 Ping-Heng Tan,1,4 Jen-Kun Cheng,1,5,6,7 Yen-Chin Liu,1,8 Ru-Rong Ji1*
Management of chronic pain, such as nerve-injury-induced neuropathic pain associated with diabetic
neuropathy, viral infection, and cancer, is a real clinical challenge. Major surgeries, such as breast and tho-
racic surgery, leg amputation, and coronary artery bypass surgery, also lead to chronic pain in 10–50% of
individuals after acute postoperative pain, partly due to surgery-induced nerve injury. Current treatments
mainly focus on blocking neurotransmission in the pain pathway and have only resulted in limited suc-
cess. Ironically, chronic opioid exposure might lead to paradoxical pain. Development of effective thera-
peutic strategies requires a better understanding of cellular mechanisms underlying the pathogenesis of
neuropathic pain. Progress in pain research points to an important role of microglial cells in the develop-
ment of chronic pain. Spinal cord microglia are strongly activated after nerve injury, surgical incision, and
chronic opioid exposure. Increasing evidence suggests that, under all these conditions, the activated mi-
croglia not only exhibit increased expression of microglial markers CD11b and Iba1, but also display ele-
vated phosphorylation of p38 mitogen-activated protein kinase. Inhibition of spinal cord p38 has been
shown to attenuate neuropathic and postoperative pain, as well as morphine-induced antinociceptive tol-
erance. Activation of p38 in spinal microglia results in increased synthesis and release of the neurotrophin
brain-derived neurotrophic factor and the proinflammatory cytokines interleukin-1β, interleukin-6, and
tumor necrosis factor-α. These microglia-released mediators can powerfully modulate spinal cord synap-
tic transmission, leading to increased excitability of dorsal horn neurons, that is, central sensitization,
partly via suppressing inhibitory synaptic transmission. Here, we review studies that support the prono-
ciceptive role of microglia in conditions of neuropathic and postoperative pain and opioid tolerance. 
We conclude that targeting microglial signaling might lead to more effective treatments for devastating
chronic pain after diabetic neuropathy, viral infection, cancer, and major surgeries, partly via improving
the analgesic efficacy of opioids.
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Microglia Activation and 
Neuropathic Pain
Microglial cells originate from bone-marrow-
derived monocytes migrating to the central ner-
vous system during the perinatal period, and they
account for 5–12% of the total cells in the cen-
tral nervous system. Under normal conditions,
microglia are ramified and thought to be quies-
cent. However, microglia under the non-injured
conditions are not really quiescent, because they
can actively sense their environment with their
ramified processes.1 After peripheral nerve injury,
microglia in the spinal cord become activated and
show dramatic changes in morphology (from
ramified to ameboid) and robust increases in the
expression of microglial markers such as CD11b
and Iba1 (Figure 1).2 Proliferation of microglia
in the spinal cord after nerve injury is also a fea-
ture of microglial activation. Under normal con-
ditions, glial cell proliferation is rarely detected.
However, robust microglial proliferation occurs
under several neuropathic pain conditions after
sciatic nerve constriction, partial sciatic nerve 
ligation, or spared nerve injury (SNI),2,3 in which
two of the three terminal branches of the sciatic
nerve are ligated, leaving the third branch, the
sural nerve, intact.4 Notably, nerve-injury-induced
cell proliferation in the spinal cord is largely re-
stricted to microglial cells, although proliferation
of other cell types, such as astrocytes, has also
been reported.5 The specific role of microglial
proliferation in the control of neuropathic pain
has not been clearly demonstrated. However,
more microglia could result in increased produc-
tion of pain mediators.
Although nerve-injury-induced morphological
changes in microglia are very striking, biochemi-
cal changes after nerve injury are more important
for microglia to induce pain. Nerve injury results
in dramatic upregulation of the ATP receptor
P2X46 and the chemokine receptor CX3CR1 in
spinal cord microglia.7,8 Spinal blockade of P2X4
and CX3CR1 signaling attenuates nerve-injury-
induced neuropathic pain.6,8 The chemokine 
receptor CCR2 and Toll-like receptor (TLR)4 also
contribute to neuropathic pain sensitization via
microglial activation,9,10 although CCR2 and TLR4
localization in microglia has not been clearly
demonstrated.
Studies from many laboratories worldwide
have demonstrated that nerve injury causes phos-
phorylation of p38 mitogen-activated protein 
kinase (MAPK) in spinal cord microglia.11,12
Phsopho-p38 (p-p38) levels are low in the spinal
cord of non-injured rats. Spinal nerve ligation in-
duces a substantial increase in p-p38 levels in the
injured side of the spinal cord, which is accom-
panied by an increase in p38 activity.11 Strikingly,
p38 is primarily if not exclusively activated in
spinal cells expressing the microglial markers.
CD11b/OX-42 and Iba1.13,14 By contrast, p-p38
is barely detected in Neuronal-nuclei-expressing
neurons, although low levels of p-p38 might be
seen occasionally. We have confirmed microglial
activation of p38 in the SNI model.15 p38 activa-
tion in spinal microglia has also been reported
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Figure 1. Microglial reaction in the spinal dorsal horn 
of rats after nerve injury and paw incision. (A) OX-42 
immunofluorescence (dark field) in the dorsal horn 1 day
after spinal nerve ligation. The lesion side shows marked
microglial activation in comparison with the contralateral
side. (B) Immunohistochemical staining (bright field) of
Iba-1 in the dorsal horn 1 day after plantar incision. The re-
active microglia in the injured side displayed a dense and
ameboid appearance in contrast to the ramified morphology
of microglia in the contralateral side. Scar bar = 100 μm.
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after ventral root lesion16 and spinal cord injury.17
Although p38 activation peaks in the first week
of nerve injury, activation is still maintained
even 3 weeks later.18 Thus, either intrathecal 
pretreatment of p38 inhibitor (e.g. SB203580 or
FR167653) or intrathecal post-treatment with 
p38 inhibitor, at early and late stages of nerve 
injury, can effectively reduce nerve injury mechan-
ical allodynia, a cardinal feature of neuropathic
pain.13–15 Consistently, minocycline, a non-
selective microglial inhibitor attenuates neuro-
pathic pain by inhibiting p38.17,19 Minocycline
only inhibits neuropathic pain in the early phase;
therefore, it might not inhibit p38 activation in
the late phase.
What causes activation of p38 and microglia
in the spinal cord? We have shown that matrix
metalloproteinase (MMP)-9 can cause microglial
activation via neuronal–glial interaction. Spinal
nerve ligation elicits a rapid increase in MMP-9
protein and activity in dorsal root ganglion
(DRG) neurons.20 Intrathecal administration of
MMP-9 induces persistent mechanical allodynia
for many days.20 Intrathecal MMP-9 also induces
drastic activation of spinal microglia, as revealed
by increased p38 phosphorylation and OX-42
expression in the spinal cord.20 A critical issue to
study MMP-9 function is how to suppress MMP-9
expression persistently in the DRG. Tan and
coauthors21 have developed an RNA interference
strategy to target gene expression in the pain 
system, using a cationic polymer, polyethyl-
eneimine, to form a “proton sponge” by utilizing
its buffering capacity, which enables polyethyl-
eneimine to buffer endosomes and induce their
rupture to release small interfering RNA (siRNA)
into the cytoplasm.21,22 We have used this siRNA
strategy to target MMP-9 in the DRG after nerve
injury. Intrathecal injections of MMP-9-specific
siRNA (2 × 5 μg) in rats effectively suppressed
spinal-nerve-ligation-induced MMP-9 upregula-
tion by > 70% in the DRG without affecting
MMP-2 levels.20 Importantly, this siRNA treat-
ment also suppressed microglia activation in the
spinal cord and delayed the development of me-
chanical allodynia.20 We found that Cy3-labeled
siRNA was heavily taken up by many DRG cells 
3 hours after intrathecal injection.22 These results
suggest that siRNA knockdown is an effective
way to study gene functions in neuropathic pain.
An association of MMP-9 with microglia activa-
tion of p38 has been validated by the finding that
intrathecal p38 inhibitor can block the MMP-9-
induced neuropathic pain symptom, mechanical
allodynia.20
MMP-9, as well as ATP and chemokines [e.g.
CC chemokine ligand (CCL) 2 and fractalkine
(FKN)/CX3CL1] are released from DRG neurons
by nerve-injury-induced discharge, which causes
activation of microglia in the spinal cord (Fig-
ure 2). It is generally believed that nerve-injury-
induced spontaneous discharge in the axons and
cell bodies of DRG neurons can drive neuro-
pathic pain.23 Indeed, blocking neural activity in
Nerve
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ATP, MMP-9, FKN
Surgery
Activated
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Figure 2. Schematic illustration of microglia-evoked pain.
Nerve injury, surgical procedures, and chronic opioid ex-
posure result in activation of microglial cells in the spinal
cord. This activation could be initiated by the release of
ATP, MMP-9, and the chemokine FKN, leading to the
phosphorylation of p38 mitogen-activated protein kinase
in microglia. Activation of p38 induces the synthesis and
release of several pain mediators including the proinflam-
matory cytokines (IL-1β and TNF-α) and BDNF from mi-
croglia. These glia-produced pain mediators can initiate
and maintain postoperative pain, neuropathic pain, and
antinociceptive tolerance of opioids, via inducing hyperex-
citability of nociceptive neurons in the spinal cord dorsal horn.
MMP = matrix metalloproteinase-9; FKN = fractalkine; p-
p38 = phospho-p38; IL-1β = interleukin-1β; TNF-α = tumor
necrosis factor-α; BDNF=brain-derived neurotrophic factor.
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the sciatic nerve by the local anesthetic bupiva-
caine can prevent nerve-injury-induced spinal mi-
croglia activation of p38 in the SNI model.15 By
contrast, blocking C-fiber activity in the sciatic
nerve with an ultrapotent capsaicin analog,
resiniferatoxin, fails to inhibit p38 activation in
this model.24 Thus, activity from large myelinated
A-fibers is also important for microglial activa-
tion after nerve injury.
Microglial Activation and 
Postoperative Pain
Growing evidence has indicated that postopera-
tive pain, traditionally regarded as acute sponta-
neously resolving pain, could become chronic and
persistent under similar processes. For example,
groin hernia repair, breast and thoracic surgery,
leg amputation, thoracotomy, and coronary 
artery bypass surgery result in chronic pain in
10–50% individuals after acute postoperative
pain, partly due to surgery-induced nerve injury.25
In light of various types of surgery in human, an
optimal animal model is essential for investigat-
ing the mechanisms and treatments of postoper-
ative pain. The most widely used surgical pain
model in rodents was developed by Brennan 
et al.26 In this incisional pain model, a longitudi-
nal incision (1 cm) was made in the plantar sur-
face deep to the muscle layers in a hind limb.26
Behaviorally, hypersensitivity to mechanical touch
and radiant heat was shown to develop immedi-
ately after surgery and lasted for 2–3 days. Many
studies have demonstrated that this model is
compatible with human incisional pain in terms
of behavioral, pharmacological, and molecular
changes.26–28 Other surgical models have also
been developed since then to mimic different
conditions of human surgery, such as: back inci-
sion,29 hindlimb incision,30 and gastrocnemius
incision as models of incisional pain; a thoraco-
tomy model31 to study surgery in nerve-rich tis-
sues; a laparotomy model32 to mimic abdominal
surgical consequences; and a skin/muscle incision
and retraction model33 to explore potentially
persistent pain following surgery of the somatic
tissues.
In our previous study,28 we found in the plan-
tar incision model that a simple brief incision at
the paw induced marked upregulation of p38
phosphorylation in the spinal dorsal horn, starting
within 1 hour, reaching a peak at 1 day, and 
declining after 3–5 days. The time course of p38
activation was compatible with that of early pain
progression after operation. Except for a few 
neurons expressing p-p38 within the first hour,
we observed that activated p38 was exclusively
expressed in microglia. However, changes in mi-
croglia surface markers (e.g. CD11b/OX-42) after
incision was found 2–3 days later, with a marked
increase from Day 3 to Day 7 after incision.28
The function of the delayed microglial reaction
remains to be investigated.
Involvement of p38 MAPK in postoperative
pain development has been confirmed by phar-
macological inhibition of p38 via the intrathecal
route. The p38 inhibitor FR167653 produces a
potent anti-inflammatory action by inhibiting
the production of interleukin (IL)-1β and tumor
necrosis factor (TNF)-α. We have found that in-
trathecal FR167653 prevents incision-induced
mechanical allodynia, and also reduces p-p38
levels in the spinal dorsal horn, but only has a
mild effect on reducing thermal hyperalgesia.28
These results support the hypothesis that p38 ac-
tivation in spinal microglial cells plays a crucial
role in the development and maintenance of post-
operative mechanical hypersensitivity. This study
has also suggested that targeting p38 in microglia
offers a novel way of preventing persistent post-
operative pain by inhibiting microglia-driven
“central sensitization”, that is, hyperactivity in
spinal cord dorsal horn neurons, a crucial mech-
anism underlying the development of persistent
pain.34 In addition, Eisenach and collaborators
have also shown that cyclooxygenase (COX)-1 is
dramatically upregulated in spinal microglia
after incision, and intrathecal administration of
a COX-1 inhibitor can attenuate post-incisional
pain for several days.35 It is tempting to postulate
that p38 activation in microglia induces COX-1
Microglia and chronic pain
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expression to drive incisional pain, although p38
can regulate many other targets (Figure 2).
Microglia Activation and Morphine
Tolerance
Opioids are the primary treatment for acute and
cancer pain.36,37 Medical practice has shifted over
recent decades, and opioid use in chronic pain
has become common. However, long-term ad-
ministration of opioids produces negative health
consequences, such as increased risk of abuse
and addiction. Prolonged administration of opi-
oids is also associated with the development of
antinociceptive tolerance, wherein higher doses
of the drug are required over time to elicit the
same degree of analgesia. Numerous animal stud-
ies have demonstrated that sustained exposure to
systemic or spinal opioids, including morphine,
DAMGO (D-Ala2, N-MePhe4, Gly-ol]-enkephalin),
fentanyl, or heroin produces paradoxical pain,
characterized as heat hyperalgesia and mechani-
cal allodynia. Opioid-induced hyperalgesia is also
found in chronic pain patients.38,39 Chronic mor-
phine exposure results in a strong upregulation of
the microglial markers CD11b and Iba1, as well
as the ATP receptors P2X4 and P2X7 in spinal
microglia.40,41 Intrathecal injections of antisense
oligodeoxynucleotides against P2X4 or P2X7 an-
tagonists prevent development of morphine tol-
erance and microglial reaction.40,41 In particular,
chronic morphine induces p38 activation in spinal
microglia, and intrathecal treatment with p38 in-
hibitor or minocycline prevents the development
of morphine tolerance.42,43
Mechanisms of Microglia-evoked Pain
Figure 2 illustrates how microglial activation
causes pain hypersensitivity after nerve injury,
surgical procedures, and chronic opioid expo-
sure. Phosphorylation of p38 in microglia via ac-
tivation of P2X4 receptor increases the synthesis
and release of the neurotrophin brain-derived
neurotrophic factor (BDNF), and BDNF could
enhance neuropathic pain via suppressing in-
hibitory synaptic transmission in the spinal cord.44
Phosphorylation of p38 in microglia also results
in increased synthesis of the proinflammatory
cytokines IL-1β, IL-6, and TNF-α, partly through ac-
tivation of the transcription factor nuclear factor-
κB.11,45 Lipopolysaccharide, a potent microglia
activator and also a TLR4 ligand, induces IL-1β
release via p38 activation in spinal microglia.46
Accumulating evidence indicates a crucial role
for IL-1β, IL-6 and TNF-α in inducing hyperac-
tivity of dorsal horn neurons, that is, central sen-
sitization, leading to pain hypersensitivity.47,48
Intrathecal administration of IL-1β, IL-6 and
TNF-α induces robust heat hyperalgesia and me-
chanical allodynia.48,49 Conversely, spinal block-
ade of these cytokines has been shown to attenuate
inflammatory and neuropathic pain, and mor-
phine tolerance.50–54 Intrathecal administration
of IL-1β induces a substantial increase in COX-2
mRNA levels in the spinal cord.55 Perfusion of
spinal cord slices with IL-1β, IL-6 or TNF-α also
activates the transcription factor cAMP response
element-binding protein,48 which is crucial for
transcription of pro-nociceptive genes such as
neurokinin-1 and COX-2, as well as long-term
neuronal plasticity in dorsal horn neurons.34 In
particular, we have found that these proinflam-
matory cytokines also have a non-transcriptional
role in pain control. They can powerfully regulate
synaptic transmission via enhancing excitatory
synaptic transmission and suppressing inhibi-
tory synaptic transmission.48 Our patch clamp
recordings in isolated spinal cord slices have re-
vealed the following. First, IL-1β and TNF-α in-
crease spontaneous excitatory postsynaptic currents
in dorsal horn neurons, and enhance 2-amino-3-
(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid-
or N-methyl D-aspartic acid-induced currents.
Second, IL-1β and IL-6 decrease spontaneous 
inhibitory postsynaptic currents in dorsal horn
neurons and suppress γ-aminobutyric acid- or
glycine-induced currents.48,49,53 Similar findings
for the actions of IL-1β have also been reported
in cultured dorsal horn neurons,56 and TNF-α
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causes disinhibition in GABAergic neurons in
spinal cord slices.57 In addition to direct effects
on synaptic transmission, TNF-α can further acti-
vate astrocytes via c-Jun N-terminal kinase, to
produce monocyte chemoattractant protein-1
(CCL2), an important chemokine for central
sensitization,58 whereas IL-1β can activate spinal
microglia via p38 phosphorylation.24,59 Of note,
morphine metabolite morphine-3-glucuronide
facilitates pain via TLR4 activation and IL-1β
release; conversely, intrathecal injection of IL-1β
antagonist and TLR4 inhibitor can potentiate
morphine analgesia.60
Conclusions and Future Directions
Chronic pain is an increasing burden for society,
affecting 20% of the population worldwide.
Current treatments that focus mostly on target-
ing neuronal excitability and transmission are
unsatisfactory. The emerging role of microglia in
pain control brought great excitement to the
pain research field. We have discussed the prono-
ciceptive role of microglia in neuropathic pain,
postoperative pain, and opioid tolerance. It is
important to point out that some of these stud-
ies have been accomplished by four Taiwanese
anesthesiologists, who are also co-authors of this
review, during their training at Harvard Medical
School. Apparently, microglia regulate chronic pain
and opioid tolerance via neuronal-glial interac-
tions (Figure 2). First, primary sensory neurons
exhibit hyperactivity after nerve injury, surgical
procedures, and chronic opioid treatment and
release potential microglial activators such as
ATP, MMP-9, and the chemokines (e.g. FKN and
monocyte chemoattractant protein-1). Second,
p38 activation in microglia leads to the produc-
tion of pain mediators such as neurotrophin and
cytokines to modulate synaptic transmission and
enhance pain. Thus, targeting microglial signal-
ing via inhibiting the actions of chemokines (e.g.
FKN or CCL2), ATP receptors (e.g. P2X4 or P2X7),
MMP-9, p38 MAPK, and/or proinflammatory 
cytokines (e.g. IL-1β, IL-6 or TNF-α) might lead to
novel therapies for chronic pain. Finally, we have
to point out that, apart from microglia, other types
of glial cells, such as astrocytes, are also impor-
tant for inflammatory and neuropathic pain.61,62
Our work in progress has shown that astrocytes
can produce tissue plasminogen activator, a pro-
tease in the spinal cord to facilitate morphine
tolerance (unpublished observations). Satellite
glial cells share similar molecular features as 
astrocytes, but are localized in the DRG in the
peripheral nervous system. Activation of satellite
cells in the DRG after morphine treatment could
antagonize morphine analgesia via release of 
IL-1β (unpublished observations). It remains to
be investigated how different types of glial cells
control pain sensitivity under various injury and
treatment conditions.
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